Publications by authors named "Jonas Kruse"
Pseudolipomas are an uncommon clinical manifestation appearing as a non-encapsulated prominence of subcutaneous fat on MRI. Post-traumatic pseudolipomas (PTLs) are thought to arise from neoadipogenesis following acute or chronic trauma. These are most commonly located on the lower extremities, gluteal, and trochanteric regions.
View Article and Find Full Text PDFBackground: The cerebellum's involvement in AD has been under-appreciated by historically labeling as a normal control in AD research.
Methods: We determined the involvement of the cerebellum in AD progression. Postmortem human and APPswe/PSEN1dE9 mice cerebellums were used to assess the cerebellar Purkinje cells (PC) by immunohistochemistry.
Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation, and transcriptional profiles. In primary MM samples, proteasome inhibitors, dinaciclib, selinexor, venetoclax, auranofin, and histone deacetylating agents had the broadest cytotoxicity.
View Article and Find Full Text PDFArticle Synopsis
- APY0201, a PIKfyve inhibitor, shows strong cellular cytotoxicity against multiple myeloma, confirmed through testing in 25 cell lines and 40% of 100 primary patient samples, especially in cases with trisomies and without t(11;14).
- When compared to other PIKfyve inhibitors, APY0201 demonstrated superior potency, effectively reducing cell viability at very low concentrations in a majority of tested cell lines.
- The treatment with APY0201 resulted in changes related to lysosomal function and autophagy, suggesting that its effectiveness in multiple myeloma may stem from disrupting these cellular processes, and establishing a predictive autophagy assay could help identify likely responsive patients.